Another phase I trial studied emactuzumab with or without paclitaxel, in adult patients with advanced solid tumors and found that both monotherapy and combination with paclitaxel was largely safe with only one grade 5 toxicity, decreased CSF-1R+ and CD68+/CD163+ macrophages in the tumor microenvironment, and achieved a 7% response rate in patients receiving combination therapy with three patients with breast cancer and one patient with ovarian cancer achieving a partial response (164). This evidence concerns the gene CSF1R and neoplasm.